BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Closes $375,000 Private Placement

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing imaging-based products for more accurate breast cancer screening, diagnosis and treatment, announced it has closed a non-brokered private placement of 1.5 million units at $0.25 per unit for gross proceeds of $375,000. Each unit includes one common share and one transferable warrant exercisable at $0.50 for three years. Proceeds will be used for general working capital. An insider acquired 100,000 units under exemptions from MI 61-101 requirements, and the company paid $3,500 and issued 14,000 broker warrants exercisable at $0.25 for three years in connection with the offering.

To view the full press release, visit https://ibn.fm/fSxYl

About Izotropic

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Announces Term Sheet for CAD$5 Million Private Placement

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.…

2 hours ago

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advances ONC010 Manufacturing Development With Nanosoft

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.…

3 hours ago

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans

Cardio Diagnostics Holdings (NASDAQ: CDIO) is a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence.…

22 hours ago

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Completes Enrollment Ahead of Schedule in Heart Attack Detection Pilot Study

HeartBeam (NASDAQ: BEAT) announced it has completed patient enrollment ahead of schedule in its ALIGN-ACS…

1 day ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Publishes Peer-Reviewed Validation of Deciparticle(TM) Platform 

Oncotelic Therapeutics (OTCQB: OTLC), together with Sapu Nano, announced the publication of a peer-reviewed manuscript in the International Journal of…

2 days ago

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches AI Agent Platform for Patient Scheduling and Care Coordination

HealthLynked (OTCQB: HLYK) announced the launch of its next-generation AI Agent Platform, a conversational voice AI…

2 days ago